Resource Center
Diagnostic Methods to Predict Outcomes for Acute Graft Versus Host Disease in Allogeneic Hematopoietic Cell Transplant Recipients
Accurate and early identification of patients at high-risk for severe acute graft versus host disease (aGVHD) and related
complications has the potential to improve patient outcomes following allogeneic hematopoietic cell transplantation (alloHCT). High-risk patients can be preemptively treated for aGVHD prior to the onset of clinical disease while low-risk patients may potentially avoid unnecessary treatment. Validation of an interpretive algorithm based on serum ST2 and REG3α levels accurately predicts risks for allo-HCT patients when testing is performed at 7 days post-transplant, at the onset of aGVHD symptoms, and ≥ 1 week after the initiation of systemic therapy
Featured Resource
Immunity Testing: CMV in Lung Transplant Patients
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.
Search the Eurofins Viracor online test directory
for the most up-to-date assay offerings and information
Test Menu